Fv-Hsp72 for CRAO

About Rubicon Biotechnology

Rubicon Biotechnology, founded in 2018 and based in the San Francisco Bay Area (with operations in Irvine and Lake Forest, CA), is pioneering a therapeutic platform centered on the intracellular delivery of Heat Shock Protein 72 (Hsp72) for cytoprotection. The company's lead asset, Fv-Hsp72, is designed to mitigate cellular damage following traumatic brain injury, retinal artery occlusion, and heart attack, as evidenced by peer-reviewed preclinical data. Rubicon's strategy is heavily reliant on non-dilutive funding from U.S. government agencies like the US Army (USAMRDC) and the National Institutes of Health (NEI), positioning it to advance key programs toward clinical development. Its focus addresses significant unmet medical needs in neurology, ophthalmology, and cardiology with a potentially first-in-class mechanism.

Therapeutic Areas